Italian multinational laboratory diagnostics firm DiaSorin is to acquire Luminex Corporation for a price of US$37 per share in an all-cash transaction, which values Luminex at approximately US$1.8bn. The cash consideration represents a premium of around 23.1% to Luminex shareholders based on the close on February 24. The acquisition will broaden DiaSorin’s positioning in the…